FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

CONDON DENNIS E 		2. Issuer Name and Ticker or Trading Symbol

BIOFORM MEDICAL INC [ BFRM ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Pres & Chief Business Officer
(Last)          (First)          (Middle)

1875 SOUTH GRANT STREET, SUITE 200 		3. Date of Earliest Transaction (MM/DD/YYYY)

2/16/2010
(Street)

SAN MATEO, CA 94402
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy)   $1.18   2/16/2010     D   (1) (2)       120000      (1) (2) 4/7/2019   Common Stock   120000   $0   0   D    
Employee Stock Option (Right to Buy)   $1.12   2/16/2010     D   (3)       603000      (3) 1/22/2019   Common Stock   603000   $0   0   D    
Director Stock Option (Right to Buy)   $1.75   2/16/2010     D   (4)       13000      (4) 1/12/2016   Common Stock   13000   $0   0   D    
Director Stock Option (Right to Buy)   $.84   2/16/2010     D   (5)       13000      (5) 1/13/2015   Common Stock   13000   $0   0   D    
Director Stock Option (Right to Buy)   $.45   2/16/2010     D   (6)       35000      (6) 1/15/2014   Common Stock   35000   $0   0   D    

Explanation of Responses:
( 1)  Vine Acquisition Corp. (the "Purchaser"), initiated a tender offer pursuant to Purchaser's offer to purchase all of the outstanding shares of BioForm Medical, Inc. (the "Issuer") at a cash purchase price of $5.45 per share, without interest thereon, and less any applicable withholding taxes, subject to the terms described in the Offer to Purchase filed with the Securities and Exchange Commission on January 15, 2010 (the "Tender Offer") and the Agreement and Plan of Merger, dated as of December 31, 2009, by and among Merz GmbH & Co. KGaA, the Purchaser and the Issuer. On the date of grant, the shares underlying this option were to vest and become exercisable as to 1/4 of the shares on 04/08/2010 and quarterly vesting thereafter, with options being fully vested four years following the date of grant. (Continued footnote in 2)
( 2)  The shares underlying this option, which were unvested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for the right to receive cash payment(s) representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options, upon the date(s) the shares underlying this option would have otherwise become vested.
( 3)  On the date of grant, the shares underlying this option were to vest and become exercisable as to 1/4 of the shares on 01/22/2010 and each anniversary thereof. 150,750 of the shares underlying these options, which were vested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for a cash payment of $652,747.50 representing the number of vested shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options. The remaining shares underlying these options, which were unvested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for the right to receive cash payment(s) representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options, upon the date(s) the shares underlying this option would have otherwise become vested.
( 4)  The shares underlying these options, which were fully vested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for a cash payment of $48,100.00, representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45. less the aggregate exercise price of the options.
( 5)  The shares underlying these options, which were fully vested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for a cash payment of $59,930.00, representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.
( 6)  The shares underlying these options, which were fully vested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for a cash payment of $175,000.00, representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
CONDON DENNIS E
1875 SOUTH GRANT STREET, SUITE 200
SAN MATEO, CA 94402 		X
Pres & Chief Business Officer

Signatures
/s/ Dennis E. Condon 2/19/2010
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Bioform Medical (MM) (NASDAQ:BFRM)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Bioform Medical (MM) Charts.
Bioform Medical (MM) (NASDAQ:BFRM)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Bioform Medical (MM) Charts.